Effect of Octreotide on the Colonic Motility in Pediatric Patients

As mentioned above.

Inclusion criteria

• Male or female and undergoing colonic manometry for a routinely accepted indication including: evaluation of chronic constipation, unexplained abdominal distension (Should have had previous diagnostic work up), recurrent fecal impaction, post Hirschsprung's disease repair, chronic intestinal pseudo-obstruction, or suspected colonic dysmotility of any other cause.
• Children aged 12 months or older who are undergoing colonic motility under the supervision of Dr. Joseph Croffie at Riley Hospital.
• In the investigator's judgment, parent(s)/guardian(s) is mentally competent to provide informed consent to participate in the study.

Exclusion criteria

• • Subjects with known or suspected allergy to octreotide.

• Subjects with known prolonged corrected QT interval (QTc) Syndrome or highest risk QTc-Prolonging Agents (including mifepristone).
• Subjects with known history of ventricular arrhythmia.
• Subjects with history of any organ transplant who are taking cyclosporine at the time of the motility study.
• Subjects with history of small bowel transplant.
• Subjects less than 12 months old.
• Subjects with severe renal impairment
• Subjects with severe hepatic impairment
• Subjects taking bromocriptine, insulin, oral hypoglycemic agents, beta blockers, calcium channel blockers, quinidine, terfenadine, pimozide, sildenafil, tadalafil, and any agents to control fluid and electrolyte imbalance